Q-omics provides the consensus-scored MTCYBP22 profile across patient tissues and cancer cell-line models. MTCYBP22 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MTCYBP22 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, MTCYBP22 RNA expression shows 4,730 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, KIRC, and STAD as cancer lineages where MTCYBP22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCYBP22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCYBP22 survival associations across molecular data types. MTCYBP22 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCYBP22 RNA expression–survival associations across cancer types. High MTCYBP22 expression shows unfavorable associations in OV and STAD, but favorable associations in UCEC, HNSC, LUSC and LUAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify UCEC as the clearest survival context for MTCYBP22 RNA expression.
This table summarizes MTCYBP22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCYBP22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCYBP22 shows lower tumor expression in KIRC and STAD. The KIRC box plot shows higher MTCYBP22 RNA expression in normal versus tumor tissue (log2 FC = −0.109, t-test p = .031).
This table shows molecular features associated with MTCYBP22 in patient tissues and cancer cell lines. In patient samples, MTCYBP22 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
